BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2020 3:42:19 PM | Browse: 1018 | Download: 1480
 |
Received |
|
2020-01-19 11:09 |
|
Peer-Review Started |
|
2020-01-19 11:10 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-01 03:24 |
|
Revised |
|
2020-06-02 12:39 |
|
Second Decision |
|
2020-06-19 10:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-19 19:11 |
|
Articles in Press |
|
2020-06-19 19:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-06-26 13:28 |
|
Typeset the Manuscript |
|
2020-07-14 01:24 |
|
Publish the Manuscript Online |
|
2020-07-14 15:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nan-Nan Zheng, Min Zhou, Fang Sun, Man-Xiu Huai, Yi Zhang, Chun-Ying Qu, Feng Shen and Lei-Ming Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81472844 |
|
| Corresponding Author |
Lei-Ming Xu, MD, PhD, Chief Doctor, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China. xuleiming@xinhuamed.com.cn |
| Key Words |
Protein arginine methyltransferase; Programmed death-ligand-1 blockade; Pancreatic cancer; Combination therapy; Tumor microenvironment; Pancreatic ductal adenocarcinoma |
| Core Tip |
Pancreatic ductal adenocarcinoma exhibits marginal responses to immune checkpoint inhibitors targeting programmed death-ligand-1 (PD-L1), and the underlying mechanism remains poorly understood. PT1001B, an inhibitor of type I protein arginine methyltransferases (PRMTs), significantly enhanced the therapeutic efficacy of anti-PD-L1 mAb. PT1001B improved antitumor immunity by inhibiting PD-L1 expression on tumor cells, upregulating tumor infiltrating CD8+ T lymphocytes and decreasing PD-1+ leukocytes. In addition, PT1001B amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation and enhanced the induction of tumor cell apoptosis. PRMT1 downregulation was correlated with PD-L1 downregulation, thus PRMT1 is a potential therapeutic target. |
| Publish Date |
2020-07-14 15:42 |
| Citation |
Zheng NN, Zhou M, Sun F, Huai MX, Zheng Y, Qu CY, Shen F, Xu LM. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J Gastroenterol 2020; 26(26): 3737-3749 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i26/3737.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i26.3737 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
